Life sciences company raises £1.4m to revolutionise organ transplantation

3rd September 2024, 1:02 pm

Life sciences company ScubaTx raises a further £1.4m to continue revolutionising organ transplantation after expanding into the North West of England life sciences ecosystem

ScubaTx has raised £1.4m in a round led by the Praetura Ventures managed GMC Life Sciences Fund By Praetura t­­o continue developing its transformative organ preservation device after expanding in the North West of England.

The funding round follows a sustained period of growth for Newcastle-founded ScubaTx, which has just opened a new office at Manchester Science Park, to complement its design and engineering, pre-clinical trial work and further engagement with future commercial partners and key opinion leaders, including in the US, where it is garnering increasing interest.

Led by David Campbell (CEO) and founded by the company’s CSO Dr William (Bill) Scott, ScubaTx uses a process called ‘persufflation’ to cool donated organs and oxygenate tissues with humidified gas at tightly controlled pressures and flow rates, extending an organ’s viability for significantly longer.

Following this latest funding round, ScubaTx has also doubled in size, appointing six new staff with hires from Greater Manchester, Cheshire and the surrounding areas to bolster its specialist team. These new hires are focused on building capabilities across operational, quality assurance and regulatory affairs, mechanical, electrical and software engineering. Alongside these recent hires, the new office on the Oxford Road Corridor, in the heart of Manchester’s innovation district, will allow the 12-strong team to draw on the wealth of experience in medical devices, software development and complex system engineering from across the region.

David Campbell, Founder and CEO at ScubaTx, said:

“Although our device may be a new concept to many, it’s been built from an established process with a long scientific history, providing a rich basis for us as we push the technique to new applications. Our new office at Manchester Science Park represents a real milestone, as we’ve transitioned from an entirely virtual company, to one with footholds across the North. While our pre-clinical and basic scientific research will continue from our Newcastle base, we’re excited to apply the local expertise and resources of Manchester’s rich life sciences innovation heritage to ScubaTx.”

Sim Singh-Landa, Investment Director at Praetura Ventures and Head of the GMC Life Sciences Fund By Praetura, said:

“This latest round of funding follows an exciting period of progression for ScubaTx, enabling the business to accelerate its goal to revolutionise the organ transplantation process, increasing the number of donated organs successfully reaching recipients. This significant innovation could have a tangible impact for transplant patients across the globe, saving countless lives, accelerating a better quality of life and reducing the burden on health systems from the growing number of patients on waiting lists.”

 

In addition to the GMC Life Sciences Fund By Praetura (a collaborative fund managed by Praetura Ventures and made up of Bruntwood SciTech, Enterprise Cheshire and Warrington and Greater Manchester Combined Authority), ScubaTx has also raised money from new and existing investors alongside a second Combined Investor Partnership grant from Innovate UK.

Next Article

The University of Manchester accredited as new member of the Good Employment Charter

The Greater Manchester Good Employment Charter has announced that The University of Manchester has been accredited as a full member. […]
Read Article